Chemistry:Batoclimab
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Identifiers | |
| CAS Number | |
| UNII | |
Batoclimab (also known as HBM9161 or HL161) is a fully human monoclonal antibody administered by subcutaneous injection. It works by inhibiting the neonatal fragment crystallizable receptor, which leads to a reduction in antibodies of the thyrotropin receptor. It is being developed to treat myasthenia gravis and thyroid eye disease.[1][2][3]
References
- ↑ Kahaly, George J.; Dolman, Peter J.; Wolf, Jan; Giers, Bert C.; Elflein, Heike M.; Jain, Amy P.; Srinivasan, Ashok; Hadjiiski, Lubomir et al. (30 June 2023). "Proof-of-Concept and Randomized, Placebo-Controlled Trials of an Fcrn Inhibitor, Batoclimab, for Thyroid Eye Disease". The Journal of Clinical Endocrinology and Metabolism 108 (12): 3122–3134. doi:10.1210/clinem/dgad381. ISSN 1945-7197. PMID 37390454. PMC 10655547. https://pubmed.ncbi.nlm.nih.gov/37390454/.
- ↑ Yan, Chong; Duan, Rui-Sheng; Yang, Huan; Li, Hai-Feng; Zou, Zhangyu; Zhang, Hua; Zhou, Hongyu; Li, Xiao-Li et al. (June 2022). "Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study". Neurology and Therapy 11 (2): 815–834. doi:10.1007/s40120-022-00345-9. PMID 35412216.
- ↑ Yap, Desmond Y. H.; Hai, Jojo; Lee, Paul C. H.; Zhou, Xueying; Lee, Michael; Zhang, Yu; Wang, Meng; Chen, Xiaoxiang (September 2021). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers". Clinical and Translational Science 14 (5): 1769–1779. doi:10.1111/cts.13019. PMID 33742786.
 |  |
